

Reference Number: FOI202122554

From: Private Individual

Date: 31 March 2022

Subject: Number of patients treated with the following drugs: Revolade (eltrombopag), Nplate (romiplostim), Doptelet (avatrombopag), Tavlesse (fostamatinib) and number of patients being treated for immune thrombocytopenia (ITP)

Q1 How many patients has your trust treated (for any disease) in the last 6 months (or the latest 6 months data you have available) with the following treatments:

- a. Revolade (eltrombopag)
- b. Nplate (romiplostim)
- c. Doptelet (avatrombopag)
- d. Tavlesse (fostamatinib)

A1

- a. 32
- b. 11
- c. Zero
- d. Zero

Q2 In the last 6 months (or the latest 6 months data you have available), how many patients has your trust treated for immune thrombocytopenia (ITP)?

A2 11

Q3 Of the patients treated for immune thrombocytopenia (ITP) in the last 6 months (or the latest 6 months data you have available), how many were treated with:

- a. rituximab
- b. mycophenolate mofetil
- c. surgery (splenectomy)

A3

- a. Zero
- b. Zero
- c. Zero

Q4 Does your trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?

A4 Yes, we have one clinical trial:

Trial name - A Phase 3b, Multi-centre, Randomized, Double-blind, Placebo controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Paediatric Subjects with Immune Thrombocytopenia for ≥ 6 Months. EUDRACT Number 2020-003232-24.

Number of patients taking part: Information exempted under Section 40: Personal data. Refer to S40 exemption detail below:

Section 40 Exemption:

The Trust is unable to respond to all or specific elements of your request where the response would indicate five or less individuals. The Trust is withholding this information under Section 40 (Personal Information) of the Freedom of Information Act (FOIA) 2000 to reduce the risk of any individuals being identified. The Trust is of the view that disclosure of such information would significantly increase the risk of individuals being identified and as such would constitute a breach of their personal data.

The Trust has applied exemption Section 40(2) of the FOIA and is therefore withholding the information as disclosure which may identify an individual would breach their rights under the Data Protection Act 2018. The grounds for application of this exemption include:

- Any data relating to patients or staff is third party data, furthermore health data is classified as sensitive personal data within the Data Protection Act 2018. As such, Section 40 (2) of the FOIA applies along with the Trusts duty of confidentiality. Therefore under s.2 (3) (f) (ii) of the FOIA, there is an absolute exemption from disclosure on the grounds that it would contravene the First Data Protection Principle.
- The Trust has a duty under the Data Protection Act 2018 and specifically the First Data Protection Principle to ensure personal data regarding staff and patients is processed fairly and lawfully. Disclosure of such data which may identify an individual, either through the data alone or other data in conjunction with that data which may identify an individual would therefore breach this principle.
- The Data Protection Act 2018 defines sensitive personal data to include data relating to the “physical or mental health or condition” of a person. Any such information about specific individuals falls within this category and disclosure of such data including statistical data, with any potential likelihood of identification would breach the Data Protection Act 2018.